

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal

Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Merck Serono (cetuximab) • Roche Products (bevacizumab) • Amgen (panitumumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Beating Bowel Cancer • Black Health Agency • Bladder and Bowel Foundation • Bowel Cancer UK • CANCERactive • Cancer Black Care • Cancer Equality • Chinese National Healthy Living Centre • Colostomy Association • Counsel and Care • Equalities National Council • europacoln • Helen Rollason Heal Cancer Charity • Ia: Ileostomy and Internal Pouch Support Group • Lynn's Bowel Cancer Campaign • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Actavis UK (oxaliplatin irinotecan) • Hospira UK (oxaliplatin, fluorouracil, irinotecan, calcium folinate, calcium levofolinate) • Goldshield (fluorouracil) • Medac UK (oxaliplatin irinotecan, disodium levofolinate, fluorouracil)

National Institute for Health and Clinical Excellence

Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Issue date: October 2010

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Muslim Council of Britain • Muslim Health Network • Ostomy Lifestyle Centre • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Coloproctologists of Great Britain • Association of Surgeons of Great Britain and Ireland • British Association for Services to the Elderly • British Association of Surgical Oncology • British Geriatrics Society • British Oncological Association • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Network Pharmacists Forum • Cancer Research UK • Pelican Cancer Foundation • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society 	<ul style="list-style-type: none"> • Merck Serono (tegafur uracil) • Pfizer (irinotecan, calcium levofolinate, calcium folinate) • Roche Products (capecitabine) • Sandoz (irinotecan) • Sanofi-Aventis (oxaliplatin) • Winthrop Pharmaceuticals (oxaliplatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bowel & Cancer Research • CORE - The Digestive Disorders Foundation • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme • Peninsula Technology Assessment Group, University of Exeter (PenTAG) <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • none

National Institute for Health and Clinical Excellence

Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Issue date: October 2010

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> • Department of Health • Heart of Birmingham Teaching Primary Care Trust • NHS Telford and Wrekin • Welsh Assembly Government 	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence

Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Issue date: October 2010

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

Cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part-review of technology appraisal 118)

Issue date: October 2010